## A-P Villani

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3864545/publications.pdf

Version: 2024-02-01

35 papers	842 citations	687363 13 h-index	28 g-index
37	37	37	1180 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Treatment of Eosinophilic Annular Erythema: Retrospective multicenter study and literature review. Annales De Dermatologie Et De Venereologie, 2022, 149, 123-127.	1.0	6
2	Unmet clinical needs and burden of disease in hidradenitis suppurativa: realâ€world experience from EU5 and US. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1597-1605.	2.4	15
3	Untargeted Metabolomics Profiling Identifies Onycholysis-Specific Signature in Psoriasis. Joint Bone Spine, 2022, , 105410.	1.6	0
4	Distal phalangeal bone erosions observed by HR-pQCT in patients with psoriatic onycholysis. Rheumatology, 2021, 60, 1176-1184.	1.9	5
5	Psoriasis unguéalÂ: diagnostic et prise en charge thérapeutique. Annales De Dermatologie Et De Vénéréologie, FMC, 2021, 1, 29-34.	0.0	O
6	Factors Determining Affected Sites in Hidradenitis Suppurativa. Dermatology, 2021, 237, 317-319.	2.1	1
7	Massive clonal expansion of polycytotoxic skin and blood CD8 <sup>+</sup> T cells in patients with toxic epidermal necrolysis. Science Advances, 2021, 7, .	10.3	20
8	Highâ€dimensional analysis defines multicytokine Tâ€cell subsets and supports a role for ILâ€21 in atopic dermatitis. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3080-3093.	5.7	6
9	Vascular inflammation in moderateâ€toâ€severe atopic dermatitis is associated with enhanced Th2 response. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3107-3121.	5.7	23
10	Traitements systémiques et risque infectieux dans le contexte de pandémie COVID-19. Annales De Dermatologie Et De Vénéréologie, FMC, 2021, 1, 5S6-5S12.	0.0	0
11	Which Factors Determine Affected Sites in Hidradenitis Suppurativa?. Dermatology, 2020, 236, 15-20.	2.1	10
12	Impact of the French guidelines on the prescribing habits of systemic treatments for moderateâ€toâ€severe psoriasis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e747-e748.	2.4	4
13	Treatment of cutaneous psoriasis before, during and after pregnancy. European Journal of Dermatology, 2020, 30, 8-13.	0.6	1
14	Are there distinct clinical and pathological features distinguishing idiopathic from drug-induced subacute cutaneous lupus erythematosus? A European retrospective multicenter study. Journal of the American Academy of Dermatology, 2019, 81, 403-411.	1.2	29
15	Tumor necrosis factor-α inhibitors for the treatment of pyoderma gangrenosum not associated with inflammatory bowel diseases: A multicenter retrospective study. Journal of the American Academy of Dermatology, 2019, 80, 1141-1143.	1.2	11
16	High prevalence of cannabis use among patients with hidradenitis suppurativa: results from the VERADDICT survey. British Journal of Dermatology, 2019, 181, 839-841.	1.5	12
17	French guidelines on the use of systemic treatments for moderateâ€toâ€severe psoriasis in adults. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 464-483.	2.4	137
18	Dermpath & Dermatology, 2019, 29, 239-240.	0.6	3

#	Article	IF	CITATIONS
19	Oral ofloxacin and clindamycin as an alternative to the classic rifampicin–clindamycin in hidradenitis suppurativa: retrospective analysis of 65 patients. British Journal of Dermatology, 2018, 178, e15-e16.	1.5	18
20	Immune-mediated skin diseases induced by chemicals and drugs. Current Opinion in Toxicology, 2018, 10, 111-116.	5.0	3
21	Image Gallery: Pyostomatitis vegetans of the tongue. British Journal of Dermatology, 2018, 179, e193-e193.	1.5	0
22	sQUIZ your knowledge $Cf$ : A recent red lesion on the forearm. European Journal of Dermatology, 2018, 28, 280-282.	0.6	0
23	sQUIZ your knowledge! Persistent facial plaques. European Journal of Dermatology, 2017, 27, 681-683.	0.6	0
24	Management of psoriatic arthritis among cutaneous psoriasis patients: from pathogenesis to therapy. Italian Journal of Dermatology and Venereology, 2017, 152, 458-473.	0.2	0
25	Application of C4d Immunohistochemistry on Routinely Processed Tissue Sections for the Diagnosis of Autoimmune Bullous Dermatoses. American Journal of Dermatopathology, 2016, 38, 186-188.	0.6	20
26	Hidradenitis suppurativa (HS): An unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases. Journal of the American Academy of Dermatology, 2016, 74, 1153-1159.	1.2	56
27	Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis. Journal of the American Academy of Dermatology, 2015, 73, 242-248.	1.2	222
28	Treatment (biotherapy excluded) of psoriatic arthritis: an appraisal of methodological quality of international guidelines. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 33-39.	2.4	6
29	Is there a psoriasis skin phenotype associated with psoriatic arthritis? Systematic literature review. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 17-26.	2.4	72
30	Evidenceâ€based recommendations on the role of dermatologists in the diagnosis and management of psoriatic arthritis: systematic review and expert opinion. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 3-12.	2.4	25
31	Symptoms dermatologists should look for in daily practice to improve detection of psoriatic arthritis in psoriasis patients: an expert group consensus. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 27-32.	2.4	24
32	Treatment for palmoplantar pustular psoriasis: systematic literature review, evidenceâ€based recommendations and expert opinion. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 13-16.	2.4	57
33	Paradoxical psoriatic arthritis in a patient with rheumatoid arthritis treated by TNFα blocker. Joint Bone Spine, 2014, 81, 455-456.	1.6	9
34	Linear Atrophoderma of Moulin: Report of 4 Cases and 20th Anniversary Case Review. Dermatology, 2013, 227, 5-9.	2.1	16
35	Vemurafenib-induced panniculitis. European Journal of Dermatology, 2013, 23, 258-260.	0.6	14